OLFML3 (Olfactomedin-like 3) is a secreted glycoprotein belonging to the olfactomedin domain-containing protein family, characterized by conserved OLF domains implicated in extracellular matrix interactions and cellular signaling. Primarily expressed during embryonic development, OLFML3 is involved in tissue morphogenesis, angiogenesis, and immune modulation. Studies suggest its role in regulating BMP (bone morphogenetic protein) signaling pathways, influencing cell adhesion, migration, and differentiation. Dysregulation of OLFML3 has been linked to pathological conditions, including cancers (e.g., colorectal, ovarian), inflammatory diseases, and fibrosis, where it may promote tumor progression or tissue remodeling.
OLFML3 antibodies are immunological tools designed to detect and quantify OLFML3 protein levels in research applications. These antibodies enable the investigation of OLFML3's spatial expression, interaction partners, and functional mechanisms via techniques like immunohistochemistry, Western blotting, and immunofluorescence. Recent interest in OLFML3 antibodies stems from their potential utility in identifying biomarkers for disease diagnosis or therapeutic targeting. However, challenges remain in characterizing OLFML3's precise molecular functions and context-dependent roles, necessitating further validation of antibody specificity across experimental models. Ongoing research aims to elucidate OLFML3's contribution to cellular microenvironments and its viability as a clinical target.